| Sep 27 |
Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround
|
| Sep 26 |
Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares
|
| Sep 23 |
Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute
|
| Sep 17 |
Crown Labs tender offer for Revance delayed, expect deal to be completed - analyst
|
| Sep 16 |
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update)
|
| Aug 29 |
How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%
|
| Aug 13 |
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?
|
| Aug 12 |
Sector Update: Health Care Stocks Slipping Late Afternoon
|
| Aug 12 |
Dow Dips 150 Points; Monday.com Posts Upbeat Earnings
|
| Aug 12 |
Crown Laboratories, Revance Enter Merger Agreement
|
